In a ground-breaking leap for medical science, we proudly unveil the world’s first Oral Dose Antibody technology—a true game-changer in healthcare. This revolutionary advancement represents a monumental shift from traditional methods, making it possible for patients to receive the powerful benefits of antibodies through a simple and very safe oral dose.

Why Is This So Special?

• Unprecedented Accessibility: No longer confined to injections or infusions, our technology allows for effortless, non-invasive administration. Imagine the ease of taking a medication as simple as a daily pill, yet powerful enough to combat diseases and support immune health.
• Enhanced Patient Experience: By eliminating the need for needles and complex administration processes, we’ve transformed the treatment experience, making it more comfortable and convenient for patients of all ages.
• Broad Impact: This innovation paves the way for wider accessibility and distribution of antibody-based treatments, potentially reaching underserved populations and revolutionizing healthcare delivery on a global scale.
• Scientific Breakthrough: Our Oral Dose Antibody technology is not just a new method—it's a leap into the future of medicine, driven by cutting-edge research and unparalleled expertise. We’ve harnessed advanced science to bring you a solution that stands alone in its category, setting a new standard for safe therapeutic efficacy and patient convenience.
Prepare to witness the dawn of a new era in healthcare. With our Oral Dose Antibody technology, we are not just introducing a product; we are redefining the way we approach treatment and patient care. Welcome to the future of medicine, where innovation meets simplicity and safety.

We have developed and registered the World’s first legitimate treatments using oral antibodies and are confident they can be used to produce better and more sustainable health solutions.

C Diff FYX, now in phase 2 clinical trial as a treatment against C Difficile bacteria infection, will replace antibiotics, with no resistance or side effects. These same antibodies can also be used to prevent hospital acquired C Difficile infection, saving $5B annually for American hospitals alone.

Positive proof of concept results for our oral antibodies have also been observed for:

• Obesity
• Traveler’s Diarrhea
• Acid Reflux
• Arthritis
• Asthma
• IBS

Other pipeline targets include

• IBD
• Covid-19
• UTI
• Stress
• Anxiety
• Depression
• Heart Disease
• Colorectal cancer
• Alzheimer’s
• Parkinson’s
• Autism

We are initially looking for financial assistance to complete phase trials of our C Difficile treatment (C Diff FYX). Please contact John Hare for more information (941-221-2505).